Prospectively randomized trials showed improved recurrence-free survival (RFS) in stage III melanoma patients with adjuvant systemic therapy with immune checkpoint inhibitors (ICI) or BRAF/MEK targeted therapy. The gene discussed is BRAF; the disease is melanoma.